E5 Pharma Company Profile
What is the competitive landscape for E5 PHARMA
E5 PHARMA has two approved drugs.
Drugs and US Patents for E5 Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E5 Pharma Inc | DIAZOXIDE | diazoxide | SUSPENSION;ORAL | 211050-001 | Dec 20, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| E5 Pharma | IVERMECTIN | ivermectin | TABLET;ORAL | 216808-001 | Mar 9, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

